- Bayer confirms full-year 2011 Group financial outlook of 5-7% organic sales growth, adjusted EBITDA over €7.5 billion, and core EPS growth of approximately 15%.
- In Q3 2011, Bayer delivered sales growth of 1% (5% adjusted for currency and portfolio effects) and adjusted EBITDA growth of 8% compared to the prior year.
- Reported net income increased 125% to €642 million compared to Q3 2010, driven by continued momentum in emerging markets and productivity measures.
- Bayer had a strong start to 2017 with growth across all business segments and raised its full-year outlook driven by Covestro's performance.
- Q1 sales increased 9% to €13.2 billion and EBITDA rose 15% to €3.9 billion.
- Pharmaceuticals had very good business development with 20% sales growth of key growth products.
- Consumer Health saw a 3% increase in sales and 2% increase in EBITDA.
- Crop Science sales grew 3% overall with encouraging 9% growth in North America.
- Bruker reported revenue growth of 2.5% year-over-year for Q1 2017 to $384.9 million, driven by acquisitions offsetting declines in organic and currency revenue.
- Non-GAAP gross margin expanded 90 basis points and non-GAAP operating margin grew 20 basis points compared to Q1 2016.
- EPS declined to $0.19 per share from $0.21 per share in Q1 2016 due to a higher effective tax rate in the current period.
Bruker reported Q2 2017 financial results with revenue increasing 11.6% year-over-year to $414.9 million. Organic revenue growth was 7.6% while acquisitions contributed 5.8% growth. The operating margin expanded 170 basis points to 12.5% of revenues due to revenue growth and 2016 restructuring benefits. Non-GAAP EPS grew 15% to $0.23 per share despite a higher effective tax rate compared to the prior year period. For the full year 2017, Bruker expects revenue to increase 4.5-6.0% and for the non-GAAP operating margin to expand 40-70 basis points.
Trinseo reported financial results for the second quarter of 2018 that were in line with prior guidance. Net income was $98 million and Adjusted EBITDA was $170 million, which included a favorable $10 million net timing impact. The company continues to make progress on its 2016-2019 growth initiatives and expects to achieve $90 million in Adjusted EBITDA growth across various segments. For Q3 2018, Trinseo provided an outlook for Net Income between $88-96 million and Adjusted EBITDA between $150-160 million. For full year 2018, the outlook is for Net Income between $393-410 million and Adjusted EBITDA between $665-685 million.
Owens Corning presented at various investor events in Q3 2017 to discuss their focus on shareholder value. The presentation discusses Owens Corning's three business segments and provides an overview of financial results including adjusted EBIT, margins, free cash flow, and return on capital. It highlights the company's track record of financial improvement and compelling investment thesis including leadership positions in attractive industries and a disciplined capital allocation strategy.
- Rockwell Automation held a fiscal year 2017 third quarter conference call on July 26, 2017 to discuss financial results and outlook.
- For the third quarter, organic sales were up 8.2% year-over-year driven by double-digit growth in Asia Pacific and Latin America. Adjusted EPS grew 14% to $1.76.
- For the full fiscal year, Rockwell is increasing its adjusted EPS guidance range to $6.60-$6.80, reflecting continued expected organic sales growth of 6% and adjusted EPS growth of 13% at the midpoint.
- WestRock reported Q3 2017 results with adjusted earnings per share of $0.74 and adjusted free cash flow of $473 million.
- They achieved $94 million in productivity initiatives and expect a synergy and performance improvement run-rate of $825 million by the end of Q4 2017.
- Guidance for fiscal year 2017 includes reaffirming adjusted free cash flow of $1.2 billion and estimating capital expenditures of $750 million.
The document is Owens Corning's presentation from November 1, 2017 focused on sharing information with investors. It discusses Owens Corning's three business segments: Insulation, Roofing, and Composites. It provides an overview of the company's financial performance in recent years, including improved earnings, margins, free cash flow, and return on capital. The presentation emphasizes Owens Corning's commitment to shareholder value and disciplined capital allocation.
- Bayer had a strong start to 2017 with growth across all business segments and raised its full-year outlook driven by Covestro's performance.
- Q1 sales increased 9% to €13.2 billion and EBITDA rose 15% to €3.9 billion.
- Pharmaceuticals had very good business development with 20% sales growth of key growth products.
- Consumer Health saw a 3% increase in sales and 2% increase in EBITDA.
- Crop Science sales grew 3% overall with encouraging 9% growth in North America.
- Bruker reported revenue growth of 2.5% year-over-year for Q1 2017 to $384.9 million, driven by acquisitions offsetting declines in organic and currency revenue.
- Non-GAAP gross margin expanded 90 basis points and non-GAAP operating margin grew 20 basis points compared to Q1 2016.
- EPS declined to $0.19 per share from $0.21 per share in Q1 2016 due to a higher effective tax rate in the current period.
Bruker reported Q2 2017 financial results with revenue increasing 11.6% year-over-year to $414.9 million. Organic revenue growth was 7.6% while acquisitions contributed 5.8% growth. The operating margin expanded 170 basis points to 12.5% of revenues due to revenue growth and 2016 restructuring benefits. Non-GAAP EPS grew 15% to $0.23 per share despite a higher effective tax rate compared to the prior year period. For the full year 2017, Bruker expects revenue to increase 4.5-6.0% and for the non-GAAP operating margin to expand 40-70 basis points.
Trinseo reported financial results for the second quarter of 2018 that were in line with prior guidance. Net income was $98 million and Adjusted EBITDA was $170 million, which included a favorable $10 million net timing impact. The company continues to make progress on its 2016-2019 growth initiatives and expects to achieve $90 million in Adjusted EBITDA growth across various segments. For Q3 2018, Trinseo provided an outlook for Net Income between $88-96 million and Adjusted EBITDA between $150-160 million. For full year 2018, the outlook is for Net Income between $393-410 million and Adjusted EBITDA between $665-685 million.
Owens Corning presented at various investor events in Q3 2017 to discuss their focus on shareholder value. The presentation discusses Owens Corning's three business segments and provides an overview of financial results including adjusted EBIT, margins, free cash flow, and return on capital. It highlights the company's track record of financial improvement and compelling investment thesis including leadership positions in attractive industries and a disciplined capital allocation strategy.
- Rockwell Automation held a fiscal year 2017 third quarter conference call on July 26, 2017 to discuss financial results and outlook.
- For the third quarter, organic sales were up 8.2% year-over-year driven by double-digit growth in Asia Pacific and Latin America. Adjusted EPS grew 14% to $1.76.
- For the full fiscal year, Rockwell is increasing its adjusted EPS guidance range to $6.60-$6.80, reflecting continued expected organic sales growth of 6% and adjusted EPS growth of 13% at the midpoint.
- WestRock reported Q3 2017 results with adjusted earnings per share of $0.74 and adjusted free cash flow of $473 million.
- They achieved $94 million in productivity initiatives and expect a synergy and performance improvement run-rate of $825 million by the end of Q4 2017.
- Guidance for fiscal year 2017 includes reaffirming adjusted free cash flow of $1.2 billion and estimating capital expenditures of $750 million.
The document is Owens Corning's presentation from November 1, 2017 focused on sharing information with investors. It discusses Owens Corning's three business segments: Insulation, Roofing, and Composites. It provides an overview of the company's financial performance in recent years, including improved earnings, margins, free cash flow, and return on capital. The presentation emphasizes Owens Corning's commitment to shareholder value and disciplined capital allocation.
Curtiss-Wright reported second quarter 2017 earnings that exceeded expectations. Revenue increased 7% to $583 million driven by growth in power generation and industrial markets. Operating income rose 22% and margins increased 190 basis points to 14.7%. For full-year 2017, Curtiss-Wright raised guidance and now expects revenue to increase 4-6% and diluted EPS to grow 6-8% to a range of $4.45 to $4.55. Management cited improving industrial demand and contributions from acquisitions for the increased outlook.
- Bruker Corporation reported financial results for Q1 2018 with total revenues increasing 12.2% year-over-year to $431.7 million.
- Organic revenue growth was 4.0% including 3.8% growth in the Scientific Instruments segment. Foreign exchange rates contributed 7.7% to total revenue growth.
- Non-GAAP earnings per share increased 26% to $0.24 compared to $0.19 in Q1 2017, driven by revenue growth and a lower tax rate partially offset by foreign exchange headwinds.
Ryder held its first quarter 2017 earnings conference call on April 25, 2017. During the call, Ryder reported earnings per share of $0.71 compared to $1.05 in the first quarter of 2016. Ryder also provided a forecast for full year 2017 earnings per share of $3.90 to $4.20, lowering its previous forecast. Ryder's business segments all saw revenue growth compared to the prior year, but earnings declined due to lower used vehicle sales and weaker commercial rental performance. Ryder also updated on its used vehicle sales and provided additional financial details from the quarter.
Owens Corning provides concise summaries of its quarterly performance and outlook. The summary focused on its three businesses: Insulation, Roofing, and Composites. It discussed financial results including EBIT margins and free cash flow generation. It also outlined drivers of future growth across end markets and an acquisition that strengthens its Insulation segment.
- Bayer reported increased sales and earnings for Q3 2017 compared to the same period last year, despite deconsolidating Covestro from its results.
- Core earnings per share (EPS) from continuing operations rose 1% to €1.53 due to sales growth, while EBITDA before special items increased 4% to €2,204 million.
- The company confirmed its full-year 2017 outlook, expecting low single-digit sales growth to €35-36 billion and slightly higher EBITDA compared to prior year.
Owens Corning presented information at investor events in June 2017. The presentation discussed Owens Corning's focus on shareholder value and provided an overview of the company's Q2 2017 performance. It summarized the company's three business segments and highlighted its improved portfolio, earnings, cash flow, and macroeconomic drivers. Owens Corning aims to invest in organic growth, pursue value-creating acquisitions, and return cash to shareholders.
- The company reported a 9% year-over-year increase in orders and a 25% increase in backlog for Q2 2017. Adjusted EBITDA remained flat at $25 million despite a 13.8% decrease in revenue.
- For the full year 2017, the company updated guidance to project revenue to decline 5-7% year-over-year and adjusted EBITDA to be between $59-69 million, an improvement from prior guidance.
- The company is making progress on strategic priorities including new product development, cost management actions, margin expansion initiatives, and embedding process improvements.
- The company reported a 17.1% increase in orders but a 28.5% decrease in revenue for Q1 2017 compared to Q1 2016. The backlog increased 0.8% year-over-year.
- The net loss was $36.0 million for Q1 2017, an improvement from a $192.7 million loss in Q1 2016. Adjusted EBITDA was negative $0.8 million compared to positive $19.5 million last year.
- New products launched at ConExpo received strong customer reception, but soft market conditions impacted the mobile cranes and tower cranes businesses in some regions. The company is focused on cost management and aligning production capacity with
Bruker Corporation reported financial results for Q4 2017 and FY 2017. In Q4, revenues increased 12.8% year-over-year to $530.5 million, driven by 4.0% organic growth, a 5.2% benefit from currency fluctuations, and 3.6% from acquisitions. Non-GAAP operating profit grew 20.4% and non-GAAP earnings per share increased 11% compared to Q4 2016. For FY 2017, revenues grew 9.6% to $1.766 billion with 3.6% organic growth, a 1.2% currency benefit, and 4.8% from acquisitions, while non-GAAP operating margins expanded.
This document provides an overview of Owens Corning for investors attending an event in August 2017. It discusses Owens Corning's three business segments: Insulation, Roofing, and Composites. It highlights how portfolio improvements over the last several years have lifted margins and returns. Free cash flow has also significantly improved. Owens Corning has a disciplined capital allocation strategy and strong cash flow outlook. The Insulation and Roofing businesses each provide details on market positions, historical performance, and growth opportunities.
This document provides an overview of Owens Corning for investors. It discusses Owens Corning's three business segments (Insulation, Roofing, Composites), highlights their market positions and financial profiles. It presents Owens Corning's investment thesis, which includes favorable macro drivers, a portfolio improved through actions taken from 2007-2016 that lifted margins and returns, and opportunities for further organic and inorganic growth. Details on specific business units and markets are also summarized.
- Masco reported strong results for the first quarter of 2016, with total sales increasing 4% year-over-year to $1.72 billion.
- All of Masco's business segments experienced sales growth in the quarter, with Plumbing Products sales up 2% and Decorative Architectural Products sales increasing 9%.
- Increased operating leverage and cost productivity led to a significant expansion in operating margins across most business segments compared to the prior year. Adjusted earnings per share increased 78% to $0.32.
The document summarizes Pfizer's first quarter 2017 earnings teleconference. It began with introductions from Chuck Triano, Senior Vice President of Investor Relations. Frank D'Amelio, Executive Vice President and CFO, then reviewed the financial results, noting revenues of $12.8 billion, reported net income of $3.1 billion and adjusted diluted EPS of $0.69. D'Amelio also reaffirmed Pfizer's full-year 2017 financial guidance. Ian Read, Chairman and CEO, provided perspectives on Pfizer's business performance and progress on pipeline assets, including expected results and regulatory filings.
- Masco reported strong first quarter 2017 results, with top line growth driven by its North American Plumbing segment. The company achieved 22 consecutive quarters of sales and operating profit growth.
- Operating leverage led to expanded margins and earnings per share exceeded expectations. The company updated its EPS target range provided in 2015.
- Plumbing Products sales increased 8% excluding foreign exchange impacts, fueled by record sales and profits at Delta. Decorative Architectural Products saw builders' hardware growth despite difficult comparisons.
- The company reported improved Q3 2017 results with orders up 21% year-over-year and backlog up 32% year-over-year. Excluding one-time items, adjusted EBITDA was up 138% year-over-year.
- For 2017, the company is maintaining guidance for revenue to be down 5-7% year-over-year and adjusted EBITDA between $59-69 million. Capital expenditures are expected to be approximately $30 million.
- The company is focused on initiatives to drive margin expansion and achieve double digit operating margins by 2020, including new product development, cost management actions, and channel excellence programs.
- Revenue for Q4 2016 was $212.2 million, up 5.3% year-over-year. Full-year revenue was $798.6 million, up 1.2% year-over-year.
- Q4 2016 operating income was $49.9 million, down 0.5% year-over-year. Full-year operating income was $180.8 million, down 5.2% year-over-year.
- Q4 2016 free cash flow was $55.2 million, up 55.5% year-over-year. Full-year free cash flow was $150.9 million, down 18.1% year-over-year.
- Pfizer reported its second quarter 2017 earnings results, with revenues of $12.9 billion, a 2% decrease from the second quarter of 2016. Net income increased 50% to $3.1 billion compared to the prior year.
- Several of Pfizer's key drugs performed strongly in the quarter, including Ibrance, Eliquis, and Xeljanz. The company also achieved regulatory approvals for new drugs and indications.
- Pfizer raised its guidance for 2017 adjusted diluted EPS to a range of $2.54 to $2.60 per share, up from its previous range of $2.50 to $2.60. The company reaffirmed the rest of its 2017 financial
Bruker reported financial results for Q4 2016 and full year 2016. Q4 revenue declined 1.6% year-over-year to $470.3 million due to weak European academic orders and soft industrial markets, offset partially by acquisitions and growth in China. However, non-GAAP operating margin expanded 210 basis points to 19.6% and non-GAAP EPS grew 21% to $0.46 due to margin improvements. For full year 2016, revenue declined 0.8% to $1.611 billion but non-GAAP operating margin increased 150 basis points to 14.8% and non-GAAP EPS rose 34% to $1.19, driven by margin expansion despite revenue declines
This document provides a summary of Greif's Q3 2017 earnings conference call held on August 31, 2017. Some key highlights include:
- Net sales increased 14% year-over-year to $962 million. Operating profit before special items increased 13% to $94.5 million.
- All of Greif's business segments saw year-over-year sales growth, with particularly strong growth in the Rigid Industrial Packaging & Services segment.
- Customer satisfaction metrics improved across most business segments compared to the prior year.
- Greif reaffirmed its full-year 2017 guidance for class A earnings per share before special items and free cash flow.
- Greif continues focusing on operational improvements,
Bapcor reported strong results for FY2016 with revenue up 82.7% and EPS growth of 31%. The acquisition of ANA contributed significantly to revenue growth. Burson Trade and Autobarn also achieved solid same store sales growth. Bapcor's strategic focus remains on growing its brands and expanding its national footprint across all divisions.
- Bayer reported positive Q3 2011 results, with adjusted sales up 5% and adjusted EBITDA up 8%
- Key strategic progress included positive regulatory milestones for new drugs and 10% organic growth in emerging markets
- Bayer reiterated full-year outlook of 5-7% organic sales growth, adjusted EBITDA over €7.5 billion, and core EPS growth of approximately 15%
The document summarizes Bayer's Q4 2011 and full year 2011 financial results and performance. It provides an overview of Bayer's sales, EBITDA, net income, cash flow and earnings per share for Q4 2011. It also discusses the performance of Bayer's business segments - HealthCare, CropScience and MaterialScience. Additionally, it reviews Bayer's progress on key pipeline projects in Pharma with potential to be blockbuster drugs. Bayer achieved its full year 2011 targets for sales, EBITDA, core EPS and net debt reduction.
Curtiss-Wright reported second quarter 2017 earnings that exceeded expectations. Revenue increased 7% to $583 million driven by growth in power generation and industrial markets. Operating income rose 22% and margins increased 190 basis points to 14.7%. For full-year 2017, Curtiss-Wright raised guidance and now expects revenue to increase 4-6% and diluted EPS to grow 6-8% to a range of $4.45 to $4.55. Management cited improving industrial demand and contributions from acquisitions for the increased outlook.
- Bruker Corporation reported financial results for Q1 2018 with total revenues increasing 12.2% year-over-year to $431.7 million.
- Organic revenue growth was 4.0% including 3.8% growth in the Scientific Instruments segment. Foreign exchange rates contributed 7.7% to total revenue growth.
- Non-GAAP earnings per share increased 26% to $0.24 compared to $0.19 in Q1 2017, driven by revenue growth and a lower tax rate partially offset by foreign exchange headwinds.
Ryder held its first quarter 2017 earnings conference call on April 25, 2017. During the call, Ryder reported earnings per share of $0.71 compared to $1.05 in the first quarter of 2016. Ryder also provided a forecast for full year 2017 earnings per share of $3.90 to $4.20, lowering its previous forecast. Ryder's business segments all saw revenue growth compared to the prior year, but earnings declined due to lower used vehicle sales and weaker commercial rental performance. Ryder also updated on its used vehicle sales and provided additional financial details from the quarter.
Owens Corning provides concise summaries of its quarterly performance and outlook. The summary focused on its three businesses: Insulation, Roofing, and Composites. It discussed financial results including EBIT margins and free cash flow generation. It also outlined drivers of future growth across end markets and an acquisition that strengthens its Insulation segment.
- Bayer reported increased sales and earnings for Q3 2017 compared to the same period last year, despite deconsolidating Covestro from its results.
- Core earnings per share (EPS) from continuing operations rose 1% to €1.53 due to sales growth, while EBITDA before special items increased 4% to €2,204 million.
- The company confirmed its full-year 2017 outlook, expecting low single-digit sales growth to €35-36 billion and slightly higher EBITDA compared to prior year.
Owens Corning presented information at investor events in June 2017. The presentation discussed Owens Corning's focus on shareholder value and provided an overview of the company's Q2 2017 performance. It summarized the company's three business segments and highlighted its improved portfolio, earnings, cash flow, and macroeconomic drivers. Owens Corning aims to invest in organic growth, pursue value-creating acquisitions, and return cash to shareholders.
- The company reported a 9% year-over-year increase in orders and a 25% increase in backlog for Q2 2017. Adjusted EBITDA remained flat at $25 million despite a 13.8% decrease in revenue.
- For the full year 2017, the company updated guidance to project revenue to decline 5-7% year-over-year and adjusted EBITDA to be between $59-69 million, an improvement from prior guidance.
- The company is making progress on strategic priorities including new product development, cost management actions, margin expansion initiatives, and embedding process improvements.
- The company reported a 17.1% increase in orders but a 28.5% decrease in revenue for Q1 2017 compared to Q1 2016. The backlog increased 0.8% year-over-year.
- The net loss was $36.0 million for Q1 2017, an improvement from a $192.7 million loss in Q1 2016. Adjusted EBITDA was negative $0.8 million compared to positive $19.5 million last year.
- New products launched at ConExpo received strong customer reception, but soft market conditions impacted the mobile cranes and tower cranes businesses in some regions. The company is focused on cost management and aligning production capacity with
Bruker Corporation reported financial results for Q4 2017 and FY 2017. In Q4, revenues increased 12.8% year-over-year to $530.5 million, driven by 4.0% organic growth, a 5.2% benefit from currency fluctuations, and 3.6% from acquisitions. Non-GAAP operating profit grew 20.4% and non-GAAP earnings per share increased 11% compared to Q4 2016. For FY 2017, revenues grew 9.6% to $1.766 billion with 3.6% organic growth, a 1.2% currency benefit, and 4.8% from acquisitions, while non-GAAP operating margins expanded.
This document provides an overview of Owens Corning for investors attending an event in August 2017. It discusses Owens Corning's three business segments: Insulation, Roofing, and Composites. It highlights how portfolio improvements over the last several years have lifted margins and returns. Free cash flow has also significantly improved. Owens Corning has a disciplined capital allocation strategy and strong cash flow outlook. The Insulation and Roofing businesses each provide details on market positions, historical performance, and growth opportunities.
This document provides an overview of Owens Corning for investors. It discusses Owens Corning's three business segments (Insulation, Roofing, Composites), highlights their market positions and financial profiles. It presents Owens Corning's investment thesis, which includes favorable macro drivers, a portfolio improved through actions taken from 2007-2016 that lifted margins and returns, and opportunities for further organic and inorganic growth. Details on specific business units and markets are also summarized.
- Masco reported strong results for the first quarter of 2016, with total sales increasing 4% year-over-year to $1.72 billion.
- All of Masco's business segments experienced sales growth in the quarter, with Plumbing Products sales up 2% and Decorative Architectural Products sales increasing 9%.
- Increased operating leverage and cost productivity led to a significant expansion in operating margins across most business segments compared to the prior year. Adjusted earnings per share increased 78% to $0.32.
The document summarizes Pfizer's first quarter 2017 earnings teleconference. It began with introductions from Chuck Triano, Senior Vice President of Investor Relations. Frank D'Amelio, Executive Vice President and CFO, then reviewed the financial results, noting revenues of $12.8 billion, reported net income of $3.1 billion and adjusted diluted EPS of $0.69. D'Amelio also reaffirmed Pfizer's full-year 2017 financial guidance. Ian Read, Chairman and CEO, provided perspectives on Pfizer's business performance and progress on pipeline assets, including expected results and regulatory filings.
- Masco reported strong first quarter 2017 results, with top line growth driven by its North American Plumbing segment. The company achieved 22 consecutive quarters of sales and operating profit growth.
- Operating leverage led to expanded margins and earnings per share exceeded expectations. The company updated its EPS target range provided in 2015.
- Plumbing Products sales increased 8% excluding foreign exchange impacts, fueled by record sales and profits at Delta. Decorative Architectural Products saw builders' hardware growth despite difficult comparisons.
- The company reported improved Q3 2017 results with orders up 21% year-over-year and backlog up 32% year-over-year. Excluding one-time items, adjusted EBITDA was up 138% year-over-year.
- For 2017, the company is maintaining guidance for revenue to be down 5-7% year-over-year and adjusted EBITDA between $59-69 million. Capital expenditures are expected to be approximately $30 million.
- The company is focused on initiatives to drive margin expansion and achieve double digit operating margins by 2020, including new product development, cost management actions, and channel excellence programs.
- Revenue for Q4 2016 was $212.2 million, up 5.3% year-over-year. Full-year revenue was $798.6 million, up 1.2% year-over-year.
- Q4 2016 operating income was $49.9 million, down 0.5% year-over-year. Full-year operating income was $180.8 million, down 5.2% year-over-year.
- Q4 2016 free cash flow was $55.2 million, up 55.5% year-over-year. Full-year free cash flow was $150.9 million, down 18.1% year-over-year.
- Pfizer reported its second quarter 2017 earnings results, with revenues of $12.9 billion, a 2% decrease from the second quarter of 2016. Net income increased 50% to $3.1 billion compared to the prior year.
- Several of Pfizer's key drugs performed strongly in the quarter, including Ibrance, Eliquis, and Xeljanz. The company also achieved regulatory approvals for new drugs and indications.
- Pfizer raised its guidance for 2017 adjusted diluted EPS to a range of $2.54 to $2.60 per share, up from its previous range of $2.50 to $2.60. The company reaffirmed the rest of its 2017 financial
Bruker reported financial results for Q4 2016 and full year 2016. Q4 revenue declined 1.6% year-over-year to $470.3 million due to weak European academic orders and soft industrial markets, offset partially by acquisitions and growth in China. However, non-GAAP operating margin expanded 210 basis points to 19.6% and non-GAAP EPS grew 21% to $0.46 due to margin improvements. For full year 2016, revenue declined 0.8% to $1.611 billion but non-GAAP operating margin increased 150 basis points to 14.8% and non-GAAP EPS rose 34% to $1.19, driven by margin expansion despite revenue declines
This document provides a summary of Greif's Q3 2017 earnings conference call held on August 31, 2017. Some key highlights include:
- Net sales increased 14% year-over-year to $962 million. Operating profit before special items increased 13% to $94.5 million.
- All of Greif's business segments saw year-over-year sales growth, with particularly strong growth in the Rigid Industrial Packaging & Services segment.
- Customer satisfaction metrics improved across most business segments compared to the prior year.
- Greif reaffirmed its full-year 2017 guidance for class A earnings per share before special items and free cash flow.
- Greif continues focusing on operational improvements,
Bapcor reported strong results for FY2016 with revenue up 82.7% and EPS growth of 31%. The acquisition of ANA contributed significantly to revenue growth. Burson Trade and Autobarn also achieved solid same store sales growth. Bapcor's strategic focus remains on growing its brands and expanding its national footprint across all divisions.
- Bayer reported positive Q3 2011 results, with adjusted sales up 5% and adjusted EBITDA up 8%
- Key strategic progress included positive regulatory milestones for new drugs and 10% organic growth in emerging markets
- Bayer reiterated full-year outlook of 5-7% organic sales growth, adjusted EBITDA over €7.5 billion, and core EPS growth of approximately 15%
The document summarizes Bayer's Q4 2011 and full year 2011 financial results and performance. It provides an overview of Bayer's sales, EBITDA, net income, cash flow and earnings per share for Q4 2011. It also discusses the performance of Bayer's business segments - HealthCare, CropScience and MaterialScience. Additionally, it reviews Bayer's progress on key pipeline projects in Pharma with potential to be blockbuster drugs. Bayer achieved its full year 2011 targets for sales, EBITDA, core EPS and net debt reduction.
Q2 2011 Investor Handout U.S. West Coast RoadshowBayer
The document summarizes a presentation by Bayer's CFO Werner Baumann to investors on the company's performance in the second quarter of 2011 and outlook. Key points include:
1) Bayer continued positive momentum in the second quarter with sales growth of 5% and adjusted EBITDA growth of 6%.
2) The company reiterated its outlook for higher sales and adjusted EBITDA in 2011.
3) Bayer plans to invest €15 billion through 2013 to maximize the value of its new product pipeline and realize opportunities in emerging markets.
This document summarizes Bayer's Q2 2012 results. It saw record sales but lower reported EBIT due to special charges. All business segments saw strong growth. Full year 2012 guidance was raised significantly, expecting 4-5% organic sales growth and around a 10% increase in core EPS. Regional performance was led by the US and emerging markets. Cash flow was down year-over-year but net debt decreased. Outlooks for each subgroup were also raised for the fiscal year.
Abengoa presented its 2011 earnings and provided an outlook for 2012. Key highlights included:
- Revenues increased 46% to 7,089 million euros and EBITDA grew 36% to 1,103 million euros in 2011.
- The company's backlog remained strong at 7.5 billion euros at the end of 2011.
- Abengoa is diversifying its business across regions and sectors through new projects in the solar, transmission, and water industries.
- The company aims to further reduce debt and continue growing through international expansion in 2012.
This document is the transcript from an investor conference call by Marijn Dekkers, CEO of a science and technology company, reporting on Q2 2011 results. Dekkers discusses financial results including 5% group sales growth. Sales increased the most in emerging economies at 7% and the US at 4%. Guidance is provided for 2011 subgroups with HealthCare, Pharma and Consumer Health expected to see low to mid single digit sales growth. CropScience sales are forecast to increase by a high single digit percentage and MaterialScience sales to increase at a higher rate than sales.
XING reported strong financial results for Q1 2012, in line with expectations. Key highlights included:
- Highest number of new members in the D-A-CH region in the last 12 quarters.
- Important new product launches planned for recruitment and advertising verticals.
- Revenue of €17.7 million and EBITDA of €4.8 million, reflecting continued investments to drive future growth.
- Strong operating cash flow of €6.5 million despite accelerated investment phase since Q3 2011.
- Telefónica Latam achieved solid revenue growth in H1 2012, driven by double digit increases in mobile revenues.
- Mobile commercial activity remained strong with high smartphone adoption rates fueling mobile data usage and revenues.
- Revenue growth was impacted by regulatory measures but still increased by over 13% on an organic basis excluding regulation effects.
- The focus on fast smartphone adoption translated to sustained growth in mobile accesses and penetration rates across Latam markets.
Ferrovial reported its 2011 full year results. The document contained forward-looking statements that are based on estimates and assumptions, and are subject to risks and uncertainties. Analysts and investors are cautioned not to place undue reliance on forward-looking statements.
Ferrovial had a strong year of cash generation, debt reduction, and divestments. Key highlights included over €1.4 billion in cash flow excluding infrastructure projects, a net cash position of €907 million excluding projects, and value obtained from divestments exceeding market expectations. Business units reported revenue and EBITDA growth across most segments.
Looking ahead, Ferrovial is well positioned with a strong balance sheet and liquidity.
Presentación de Resultados Ferrovial 2011Ferrovial
Ferrovial reported its 2011 full year results. The document contained forward-looking statements that are based on estimates and assumptions, and are subject to risks and uncertainties. Analysts and investors are cautioned not to place undue reliance on forward-looking statements.
Ferrovial had a strong year of cash generation, debt reduction, and divestments. Key highlights included over €1.4 billion in cash flow excluding infrastructure projects, a net cash position of €907 million excluding projects, and value obtained from divestments exceeding market expectations. Business units reported revenue and EBITDA growth across most segments. Ferrovial is well positioned with a strong balance sheet and liquidity to invest in future growth opportunities
- Deutsche Telekom reported Q1 2012 results with group revenue of €14.4 billion, a 1.1% decline year-over-year, but an improved organic decline of 1.7%. Adjusted EBITDA was stable at €4.5 billion.
- In Germany, revenue declined 2.3% organically due to lower voice and wholesale revenues, but adjusted EBITDA margin improved further to 40.7% due to cost savings. Mobile data revenue grew 20% and smartphone sales were strong.
- In the US, revenues declined 2.3% in US dollars but adjusted EBITDA grew 8% to US$1.3 billion due to cost reductions, with the margin improving
In the first quarter of 2008, Credit Suisse reported a net loss. While most business divisions performed well, losses from valuation reductions in leveraged finance and structured products totaled CHF 5.3 billion. The bank maintained a strong capital and liquidity position with a Tier 1 capital ratio of 9.8%. Looking ahead, Credit Suisse is well positioned to create long-term value by seizing opportunities arising from market dislocation.
1) SEB reported an operating profit of SEK 2.4 billion in Q1 2009, driven by strong net interest income which increased 40% due to falling interest rates.
2) Costs were well under control and unchanged on a comparable basis despite FX effects. A cost management program has reduced staff by 230 FTEs in Q1 2009.
3) The bank strengthened its position in merchant banking in the Nordic region and increased trade finance portfolio volumes by 77% compared to Q1 2007.
The document provides an overview of Banco Santander's financial performance for the first nine months of 2011. Some key points:
- Profits were down 13% compared to the same period last year, impacted by lower revenues from financial markets and higher provisions for loan losses in the current economic environment.
- However, the bank has maintained solid basic revenue generation driven by growth in Latin America, consumer finance, and the acquisition of BZ WBK.
- Liquidity and capital positions remain strong, with capital gains expected in Q4 that will be used to further strengthen the balance sheet.
- Expenses are being tightly controlled to offset pressure on revenues, though costs related to acquisitions
Apresentação de resultados 3 T 2011 Banco SantanderBANCO SANTANDER
The document provides an overview of Banco Santander's financial performance for the first nine months of 2011. Some key points:
- Profits were down 13% compared to the same period last year, impacted by lower revenues from financial markets and higher provisions for loan losses in the current economic environment.
- However, the bank has maintained solid basic revenue generation from net interest income, fees, and insurance. Revenues increased 6% overall compared to peers.
- While macroeconomic conditions worsened in the third quarter of 2011 due to factors like the sovereign debt crisis, Santander has a good liquidity and capital position with a solid balance sheet.
- Capital gains expected in the fourth quarter will
The document provides an executive summary and highlights for Q1 2009 from SEB's CFO Jan Erik Back. Key points include:
- Operating profit was SEK 4.8 billion before provisions despite doubling collective provisions in Baltic countries.
- Net interest income increased 40% due to falling interest rates. Costs remained stable through cost management programs.
- Merchant Banking strengthened its position in the Nordic markets and supported rising client exports.
- Provisions were increased conservatively, especially in Baltic countries, with impaired loans at 2.9% of exposure.
- A successful rights issue added SEK 15 billion in new capital, strengthening the capital position.
1. Santander reported solid results for 2011, with net interest income and fees increasing by 6.0% over 2010.
2. However, larger provisions for loan losses, which increased by 3.0% over 2010, prevented profits from feeding through.
3. As a result, attributable profit was 5,351 million euros, lower than in 2010 due to the larger provisions made.
This document summarizes Bayer's investor conference call regarding its fiscal year and fourth quarter 2012 results.
1) Bayer achieved record operational and financial results in 2012, with all business subgroups contributing to top and bottom line growth. Organic sales grew 5% to around €40 billion, driven by the LifeSciences division. Special charges resulted in reported EBITDA and net income at prior year levels.
2) In Q4 2012, Bayer finished strongly with sales growth of 6% and adjusted EBITDA and core EPS growth of 18% and 3% respectively. All business subgroups increased sales and earnings year-over-year.
3) For 2013, Bayer projects continuing record performance with
Please, dial in 5 minutes before the scheduled time.
The presentation will be available on our website: www.lpsb.com.br
Thank you for your participation.
Similar to Bayer Investor Presentation Roadshow Frankfurt (20)
This document provides an overview of Bayer's Q3 2023 investor webinar. Key points include:
- Q3 sales were below prior year due to currency headwinds, with core EPS and free cash flow also declining.
- Full year 2023 outlook is confirmed, with estimated currency impact reducing EBITDA.
- Crop Science sales declined year-over-year mainly due to lower glyphosate prices, though the core business grew with strong pricing.
- Pharmaceuticals sales grew slightly, with launch assets and Eylea performing well despite a soft mature portfolio.
- The pipeline is progressing with several studies starting or expected to report.
Crop Science sales are expected to decline 5% due to a 50% drop in glyphosate sales returning to 2020 levels, while the core business is forecast to grow 5-7%. Pharmaceutical sales are projected to be flat as growth from new products offsets declines. Consumer Health sales may rise 1% despite supply constraints. The outlook assumes €1.7bn in negative currency effects and €2-3bn in litigation settlement costs.
Bayer held an investor conference call on May 11th, 2023 to discuss financial results for Q1 2023 and provide an outlook for the full year. Key highlights include:
- Q1 2023 sales were €8.4 billion, down 2% year-over-year due to a decline in glyphosate sales, though the remaining portfolio grew by 8%.
- Full year 2023 guidance was confirmed towards the lower end of the previous range, with sales expected to grow 2-3% and EBITDA between €12.5-13 billion.
- Crop Science sales are expected to grow 1.5% for the full year, with a 30-35% decline in glyphosate
Bayer held an investor conference call to discuss its Q3 2022 results. The CEO and CFO provided an overview of the company's financial performance, with all divisions reporting sales and earnings growth. Bayer remains on track to meet its full-year guidance targets despite cost inflation. The presentations focused on business updates and divisional results for Crop Science, Pharmaceuticals, and Consumer Health. Forecasts were also confirmed for key financial metrics and each division's performance for full-year 2022.
Bayer hosted an investor conference call to report its Q2 2022 results and raise its full-year 2022 guidance. Key highlights include:
- Q2 sales increased 18% to €12.8 billion driven by double-digit growth across all divisions.
- Full-year 2022 group sales are expected to increase to €47-48 billion and EBITDA margin is forecast at 26-27%.
- Crop Science sales increased 29% in Q2 and full-year growth is expected to be around 13%. Strong pricing is outpacing cost inflation.
- Pharmaceuticals and Consumer Health also posted sales growth in Q2 and their full-year outlooks were increased.
- Higher sales and
This document summarizes the key points from an investor conference call for Bayer's Q1 2022 results. Bayer reported strong sales and earnings growth in Q1 2022, driven by double-digit increases in Crop Science. All divisions outpaced expectations. Bayer also confirmed full-year 2022 guidance, expecting continued sales growth of around 5% despite inflationary pressures. Key priorities for 2022 include maintaining supply chain stability and offsetting cost inflation through pricing and efficiency measures.
Bayer reported strong financial results for FY 2021 despite challenges from currency headwinds and inflation. Group sales increased 7% to €44.1 billion driven by growth across all divisions. Core EPS rose to €6.51. Bayer expects continued sales and earnings growth in 2022, forecasting sales of ~€46 billion and Core EPS of ~€7.00 at constant currencies. Key assumptions include mid-single digit growth in Crop Science and Consumer Health and low single digit growth in Pharmaceuticals.
The document provides a summary of Bayer's Q3 2021 investor conference call. Key highlights include:
- Bayer reported double-digit sales and earnings growth in Q3 2021, driven by strong performances in Crop Science and Consumer Health.
- Full-year 2021 guidance was updated to reflect increased sales growth expectations for Crop Science and Consumer Health, while other group KPI guidance remained unchanged.
- By division, Crop Science delivered particularly strong year-over-year growth in sales and earnings. Pharma and Consumer Health also progressed well despite currency headwinds.
So in summary, Bayer delivered a strong Q3 with sales and profit increases, led by Crop Science. Full-year guidance was
The document provides an investor conference call summary for Bayer's Q2 2021 results. It includes the following key points:
- Bayer increased its full-year 2021 guidance for sales, EBITDA margin, core EPS, and net financial debt due to strong first half performance.
- All business divisions (Crop Science, Pharmaceuticals, Consumer Health) contributed to sales growth in Q2 2021 and are expected to grow for the full year.
- EBITDA before special items was lower in Q2 2021 due to currency headwinds, but margins are expected to improve for the full year.
- Free cash flow was impacted by litigation settlement payouts of €0.9 billion
This document provides a summary of Bayer's Q1 2021 earnings results conference call. It includes:
1) Bayer reported solid sales growth in Q1 2021 driven by its Crop Science division, but currency headwinds masked the underlying performance.
2) All divisions showed good underlying momentum despite currency impacts, with Crop Science up 6% at constant currencies and Pharma flat at constant currencies.
3) Bayer reconfirmed its full-year 2021 outlook despite challenges in Q1, expecting sales of €42-43 billion, Core EPS of €6.10-€6.30, and free cash flow of €36-37 billion at constant currencies.
Bayer reported financial results for full-year and Q4 2020. Despite currency headwinds, the company achieved its updated guidance for sales, EBITDA margin, core EPS and free cash flow. For 2021, Bayer expects sales of €42-43 billion, an EBITDA margin of around 27%, and core EPS of €6.10-€6.30. However, currency effects are expected to reduce sales by around €2 billion and core EPS by around €0.50 compared to constant currencies. Free cash flow is guided to be negative €3-4 billion due to planned litigation settlements of around €8 billion.
Bayer reported third quarter 2020 results with sales down 5% currency-adjusted to €8.5 billion. EBITDA declined 21% to €1.8 billion due to negative currency effects and higher product returns in Crop Science. Core EPS fell 30% to €0.81 per share. The company confirmed its currency-adjusted full-year outlook despite challenges in Crop Science. Free cash flow was negative €2 million due to settlement payments.
Werner Baumann, CEO of Bayer, and Wolfgang Nickl, CFO of Bayer, presented results from Bayer's Q2 2020 investor conference call. Despite challenges from COVID-19, Bayer reported solid results with sales of €10.054 billion and EBITDA before special items of €2.883 billion, up 6% year-over-year. Free cash flow increased 87% year-over-year to €1.59 billion. For the second half of 2020, Bayer expects continued impacts from COVID-19 and is focusing on cash and cost management. Bayer updated full-year 2020 guidance with sales expected between €42-43 billion and free cash flow between -€0.
Presentation for Bayer's Q1 2020 Investor Con-ference Call on April 27, 2020Bayer
The document summarizes Bayer's Q1 2020 earnings results and provides an outlook for 2020. Key highlights include:
- Q1 sales increased 6% to €12.8 billion driven by growth in Crop Science and Pharmaceuticals. EBITDA rose 10% to €4.4 billion.
- All business segments saw increased demand related to the COVID-19 pandemic. Crop Science had strong growth in insecticides and herbicides. Pharmaceuticals was led by Xarelto growth. Consumer Health saw elevated demand across categories.
- The outlook acknowledges COVID-19 uncertainty and focuses on maintaining operations, progressing the pipeline, continuing integration efforts, and realizing efficiency programs. Net debt was largely unchanged from year
Bayer reported its FY/Q4 2019 results, achieving its guidance targets. Sales were €43.5 billion, EBITDA was €11.5 billion, and core EPS was €6.40. Each business division performed well, with Crop Science benefiting from integration synergies, Pharmaceuticals growing due to drugs like Xarelto and Eylea, and Consumer Health returning to peer growth. Bayer also progressed on portfolio measures, signing agreements to divest its Animal Health division and other smaller businesses. Looking ahead, Bayer provided guidance for 2020 of continued sales and earnings growth.
Bayer reported its Q3 2019 results with continued growth across all divisions. Key highlights include:
- Group sales increased 5% to €9.8 billion driven by strong growth in Pharmaceuticals and Crop Science.
- EBITDA before special items grew 8% to €2.3 billion with margins up 30 basis points.
- Core EPS increased 6% to €1.16. Free cash flow grew 13% to €1.3 billion.
- Guidance for 2019 was confirmed with sales of ~€46 billion, EBITDA before special items of ~€12.2 billion, and core EPS of ~€6.80.
Crop Science Summer Technology Showcase August 1, 2019Bayer
Keynote presentations by Werner Baumann, Liam Cond, Bob Reiter and Mike Stern at the Crop Science Summer Technology Showcase on August 1, 2019 in the Bayer Chesterfield Research Center, Missouri, U.S.A.
The document summarizes Bayer's Q2 2019 earnings results. Key points include:
- Sales increased 21% to €11.5 billion (+1% at constant currencies) driven by the Monsanto acquisition.
- EBITDA before special items grew 25% to €2.9 billion with margins up 70 basis points.
- Core EPS increased 6% to €1.62.
- Free cash flow was €751 million, impacted by timing effects from the prior year period.
- Guidance for 2019 was confirmed despite ambitious targets.
A toxic combination of 15 years of low growth, and four decades of high inequality, has left Britain poorer and falling behind its peers. Productivity growth is weak and public investment is low, while wages today are no higher than they were before the financial crisis. Britain needs a new economic strategy to lift itself out of stagnation.
Scotland is in many ways a microcosm of this challenge. It has become a hub for creative industries, is home to several world-class universities and a thriving community of businesses – strengths that need to be harness and leveraged. But it also has high levels of deprivation, with homelessness reaching a record high and nearly half a million people living in very deep poverty last year. Scotland won’t be truly thriving unless it finds ways to ensure that all its inhabitants benefit from growth and investment. This is the central challenge facing policy makers both in Holyrood and Westminster.
What should a new national economic strategy for Scotland include? What would the pursuit of stronger economic growth mean for local, national and UK-wide policy makers? How will economic change affect the jobs we do, the places we live and the businesses we work for? And what are the prospects for cities like Glasgow, and nations like Scotland, in rising to these challenges?
South Dakota State University degree offer diploma Transcriptynfqplhm
办理美国SDSU毕业证书制作南达科他州立大学假文凭定制Q微168899991做SDSU留信网教留服认证海牙认证改SDSU成绩单GPA做SDSU假学位证假文凭高仿毕业证GRE代考如何申请南达科他州立大学South Dakota State University degree offer diploma Transcript
Explore the world of investments with an in-depth comparison of the stock market and real estate. Understand their fundamentals, risks, returns, and diversification strategies to make informed financial decisions that align with your goals.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
“Amidst Tempered Optimism” Main economic trends in May 2024 based on the results of the New Monthly Enterprises Survey, #NRES
On 12 June 2024 the Institute for Economic Research and Policy Consulting (IER) held an online event “Economic Trends from a Business Perspective (May 2024)”.
During the event, the results of the 25-th monthly survey of business executives “Ukrainian Business during the war”, which was conducted in May 2024, were presented.
The field stage of the 25-th wave lasted from May 20 to May 31, 2024. In May, 532 companies were surveyed.
The enterprise managers compared the work results in May 2024 with April, assessed the indicators at the time of the survey (May 2024), and gave forecasts for the next two, three, or six months, depending on the question. In certain issues (where indicated), the work results were compared with the pre-war period (before February 24, 2022).
✅ More survey results in the presentation.
✅ Video presentation: https://youtu.be/4ZvsSKd1MzE
Discovering Delhi - India's Cultural Capital.pptxcosmo-soil
Delhi, the heartbeat of India, offers a rich blend of history, culture, and modernity. From iconic landmarks like the Red Fort to bustling commercial hubs and vibrant culinary scenes, Delhi's real estate landscape is dynamic and diverse. Discover the essence of India's capital, where tradition meets innovation.
Madhya Pradesh, the "Heart of India," boasts a rich tapestry of culture and heritage, from ancient dynasties to modern developments. Explore its land records, historical landmarks, and vibrant traditions. From agricultural expanses to urban growth, Madhya Pradesh offers a unique blend of the ancient and modern.
Dr. Alyce Su Cover Story - China's Investment Leadermsthrill
In World Expo 2010 Shanghai – the most visited Expo in the World History
https://www.britannica.com/event/Expo-Shanghai-2010
China’s official organizer of the Expo, CCPIT (China Council for the Promotion of International Trade https://en.ccpit.org/) has chosen Dr. Alyce Su as the Cover Person with Cover Story, in the Expo’s official magazine distributed throughout the Expo, showcasing China’s New Generation of Leaders to the World.
Budgeting as a Control Tool in Government Accounting in Nigeria
Being a Paper Presented at the Nigerian Maritime Administration and Safety Agency (NIMASA) Budget Office Staff at Sojourner Hotel, GRA, Ikeja Lagos on Saturday 8th June, 2024.
2. Disclaimer
This presentation may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here.
These factors include those discussed in Bayer’s public reports which are
available on the Bayer website at www.bayer.com.
The company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments.
3. Das Bild k ann zurzeit nicht angezeigt werden.
3rd quarter 2011
Group Outlook confirmed
Page 1 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
4. 3rd Quarter 2011 –
Bayer Confirms Group Outlook
Delivered growth and performance, adj. sales up 5%, adj. EBITDA up 8%, reported
EPS +123%, Core EPS +18%
Further strategic progress:
Innovation pipeline: Xarelto: positive AdCom vote, positive CHMP opinion and
successful ATLAS trial; Alpharadin: FDA fast track designation; Regorafenib: phase III
mCRC stopped early on success
Emerging markets: 10% organic growth
Productivity: Group wide restructuring plans with €320 million annualised savings
already implemented
Full-year 2011 Group financial outlook reiterated: On track for 5-7% organic
sales growth, adj. EBITDA > €7.5bn and Core EPS growth of ~15%
Page 2 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
5. 3rd Quarter 2011 –
Successful Development Continued
Q3‘11 ∆% Highlights of Financial Results
€ million € million
Sales 8,670 +1 (+5) All subgroups contributed to sales
EBITDA
growth
- reported 1,731 +41
Continuing momentum in emerging
- adjusted 1,805 +8
markets
EBIT
- reported 1,099 +95 Adj. EBITDA raised on lower costs
- adjusted 1,174 +17 at HealthCare and higher volumes
Net income 642 +125
at CropScience. MaterialScience
lower due to higher raw material and
Net cash flow 1,577 +1
energy costs
Free operating cash flow 1,223 +5
EPS Reported EBIT impacted by net
- reported 0.78€ +123 special charges of €75m (prev. year
- core 1.12€ +18 €436m)
( ) = Fx & portfolio adjusted
Page 3 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
6. 3rd Quarter 2011 –
Cash Flow And Net Debt Development
Q3 2011 Cash Flow Net Debt Development
In € million In € billion
-0.4
GCF NCF Invest- oFCF
cont. ments
7.4 7.0
1,327 1,577 354 1,223
∆%
y-o-y +50 +1 -10 +5
Q2´11 Q3´11
Page 4 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
10. Full Year 2011 –
Group Outlook Confirmed
Sales ∆ Fx and portfolio adjusted, EBITDA pre-special items
2011E 2011E
2010 ∆
Original Actual1
Sales 4-6% 5-7% to
(Fx & portf. €35.1bn +8%
adjusted) €35-36bn €36-37bn
adj. Improve
€7.1bn +10% > €7.5bn
EBITDA toward €7.5bn
Core EPS €4.19 +15% ~10% ∽15%
1 As published with Q3 stockholder’s newsletter
Outlook depends on specific planning assumptions
Page 8 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011 as detailed in the Annual/ Quarterly Report
11. Fiscal 2011 –
Guidance By Subgroup
Updated:
Low-single digit (prev.: low- to mid-single digit) increase of sales.
HealthCare Expect adjusted EBITDA to grow by a mid-single digit percentage
to at least €4.6bn (prev.: small improvement).
Updated:
Expect virtually unchanged or only slightly higher sales (prev.:
Pharma low- to mid-single digit increase). Plan to increase adj. EBITDA by
about 5%, improving the adj. EBITDA margin to approx. 30%
(prev.: raise adj. EBITDA margin).
Consumer Unchanged:
Health Mid-single digit growth of sales and adj. EBITDA.
Updated:
High-single-digit percentage higher sales and growth of adj.
CropScience EBITDA by more than 20% (prev.: about 20%) compared to weak
prior year.
Updated:
Higher Q4’11 sales but lower adj. EBITDA than in Q4’10 in view of
continued increases in raw material and energy costs. Expect to
MaterialScience raise full-year sales by high-single-digit, posting slightly lower adj.
EBITDA in the region of €1.3bn (prev.: grow adj. EBITDA at a
higher rate than sales).
Outlook depends on specific planning assumptions
Page 9 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011 as detailed in the Annual/ Quarterly Report
12. Building a World-Class
Innovation Company
Page 10 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
13. Building A World-Class Innovation
Company
Portfolio Growth Productivity
Build on leading industry Invest in innovation Decomplex structures
position in all 3 capabilities and processes
subgroups
Maximize value of new Implement two-year
Enhance competitive product pipeline strength group restructuring plan
position
Realize emerging market
opportunity
Target is to deliver mid-single digit organic sales growth in 2011
and to invest €15bn in growth during 2011 - 2013
Page 11 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
14. Bayer –
A Leader in Its Markets
€16.9bn HealthCare
Pharmaceuticals €10.9bn,
leading positions in key categories
Consumer Health €6.0bn,
20% OTC pharmaceuticals, blood glucose meters and
50% veterinary medicines, global #2-4
€6.8bn CropScience
Agrochemicals and seeds & traits,
global #2 in agrochemicals
30%
€10.2bn MaterialScience
Polyurethanes and polycarbonates,
global #1/2
Sales 2010: €35.1bn
Break-down excluding reconciliation
Page 12 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
15. New Product
Pipeline Strength
Page 13 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
16. Promising Late-Stage Pharma Pipeline
What it does Status
Cardiology
1st indication launched, filed;
Xarelto inhibits blood clot formation
phase III
lowers blood pressure in the
Riociguat lung
phase III
inhibits enzymes important for launched, additional indications
Nexavar tumor growth in phase II/III
Oncology
inhibits enzymes important for CORRECT trial (phase IIII) in
Regorafenib tumor growth CRC stopped early on success
targeted treatment of bone ALSYMPCA trial (phase III)
Alpharadin metastases in prostate cancer stopped early on success
Diseases
inhibits formation of new blood
Eye
VEGF Trap-Eye vessels
1st indication filed; phase III
Page 14 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
17. Xarelto –
Novel Direct Factor Xa Inhibitor
Large global program involving over 75,000 patients
Met primary efficacy endpoints in 9 phase III studies:
RECORD 1-4, EINSTEIN DVT and EINSTEIN Extension; Rocket AF; ATLAS
TIMI51; MAGELLAN
Marketing & regulatory status:
Launched in >85 countries for VTE prevention following total knee / hip
replacement surgery
Filed for stroke prevention in patients with atrial fibrillation (SPAF) in all major
regions
Positive FDA AdCom vote on approvability in SPAF
European Committee (CHMP) recommends approval in SPAF and DVT
treatment
ATLAS TIMI51 phase III trial (ACS) met primary efficacy endpoint; data to be
presented at AHA (Nov. 13, 2011); filing planned for end 2011
EINSTEIN PE phase III program ongoing – data expected
end 2011/early 2012
DVT: deep vein thrombosis
VTE: venous thromboembolism
Page 15 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
18. VEGF Trap-Eye –
Fusion Protein To Combat Eye Diseases
In-licensed from Regeneron – Bayer has exclusive marketing rights ex-US
Met primary efficacy endpoint in 4 phase III studies (VIEW I & II, Copernicus
& Galileo)
Submitted for marketing approval to European and Japanese health
authorities for wet age related macular degeneration1
Filing for central retinal vein occlusion planned for 2012
Additional studies in diabetic macular edema and myopic choroidal
neovascularization ongoing
1 US submission (February 2011) by Regeneron
Page 16 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
19. Alpharadin – New Opportunity to Treat
Bone Metastases
Alpha-pharmaceutical (based on 223Radium, delivering highly energetic,
short ranging radiation) - in-licensed from Algeta
Radium as natural bone seeker targeting bone metastases
ALSYMPCA (phase III) in patients with bone metastases in prostate cancer
(HRPC) stopped early - Alpharadin demonstrated 44% improvement in
overall survival
Filing targeted mid 2012
Fast track status granted by FDA
Tumor cells
Newly formed
bone
Bone metastases Radium-223 deposition Radium-223: highly localized tumor cell killing
HRPC: symptomatic hormone-refractory prostate cancer
Page 17 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
20. Regorafenib –
New Treatment Option in Cancer
Oral multi-kinase inhibitor of angiogenic, stromal and oncogenic receptor
tyrosine kinases
Currently studied in late-stage clinical trials in colorectal and gastrointestinal
stromal tumors (GIST)
CORRECT phase III trial in metastatic colorectal cancer* (mCRC) stopped
early on success (Oct ‘11)
Study met its primary endpoint of significantly improving overall survival
Full data expected to be presented at a scientific congress in Q1’12
Phase III program in GIST ongoing, expect results early 2012
FDA granted orphan drug (GIST) and Fast Track (GIST & mCRC)
designation
* for patients whose disease has progressed after
approved standard therapies
Page 18 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
21. CropScience –
Innovation Leadership
R&D spending in € million
Best-in-class R&D pipeline
>850
23 new agrochemical active ingredients
722 launched since 2000, generated sales of €2bn
664 in 2009
Launched >45 AgChem formulations and
>170 seed varieties since 2010
Planning to launch 4 new molecules between
2012 and 2015
Refocus R&D: BioScience investment
significantly increased
2005 2010 2015e
AgChem BioScience
Page 19 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
22. MaterialScience –
World-Class Applications Research
Bayseal ® Baytherm®
Creates a seamless air Combines high mechanical
barrier system working like a strength with high insulating
building envelope capacity and low weight
Makrolon®
DurFlex® Forming lightweight exterior
Improving noise reduction car body parts from
and economics of rail track polycarbonate
operations
Bayblend® FR Bayfol Reflex ®
A new safety concept for car Actuators out of polymers
batteries to make housings give tactile feedback precisely
flame retardant adjusted to requirements
Makrofol®ID Baycusan®
Film for ID cards providing Solvent-free polyurethane
scratch resistance and based polymers for cosmetic
protecting against counterfeit applications
Page 20 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
23. Opportunity
Emerging Markets
Page 21 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
24. 9 Months 2011 –
Emerging Markets Leading The Growth
9M’2011 Group sales by region Emerging Economies
+9%
USA Emerging ~3,800
+4% Economies¹
20% 36% +11% +10%
19% 36%
~2,900
+14%
~1,700 +13%
34% 11% ~1,300
Western Europe Others²
+5% +5%
Group €27,337m; +7% Emerging Latin Eastern Africa &
Asia³ America Europe Middle East
In € million, ∆% yoy Fx adjusted ¹ Emerging economies include: Latin America, Asia w/o Japan, Australia,
New Zealand, Africa and Middle East incl. Turkey, Eastern Europe
² Others = Japan, Australia, New Zealand, Canada
³ Emerging Asia = Asia w/o Japan, Australia, New Zealand
Page 22 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
25. All BRIC-Countries in Our Most
Important Country Portfolio
Sales in € bn ∆% yoy Fx adjusted
Sales by country full year 2010
7.0 +0%
+7%
3.0
+30%
2.5
2.0
+6%
1.5 +10%
-5% +6%
1.0
0%
+5% +1% +5%
0.5 +3% +23% +12%
*
Page 23 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011 *Greater China includes PR China, Hongkong, Macau and Taiwan
26. Bayer is One of The Leading International
HealthCare Companies in China
Sales in € million; ∆% y-o-y Fx adjusted
Strong growth
HealthCare 9M’2011 Driven by Pharmaceuticals (+27% yoy)
€713m +24% y-o-y (Fx-adj.)*
1,000 sales representatives to be added
through 2011
Significant investment commitment
Approx. 5,300 employees (2010)
€100m over 5 years to set-up a global
R&D center in China
Top products growth in 9M‘2011*
Beijing manufacturing site expansion
Aspirin +48% (~€45m through 2015)
Adalat +30%
Partnership with Tsinghua University
Avelox +24%
(joint drug discovery, student support)
Glucobay +23%
Ultravist +14%
* People‘s Republic of China
Page 24 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
27. €1bn New Investment Plan
at MaterialScience in China
China’s importance further growing Commitment to growth in China
China already is the world’s largest PCS €2.1bn investment program in integrated
market polymer site in Shanghai, China until 2012
China is set to become the world’s largest PUR New investment of approx. €1bn in Shanghai
market by 2015 by 2016 to
Increase MDI capacity to 1,000kt/year
More than double PCS capacity to
500kt/year
Increase HDI capacity, new 50kt/year
line planned
Transfer of PCS Headquarters from
Leverkusen to Shanghai
Increasing downstream presence (investment
of €110m by 2012)
PCS = Polycarbonates
PUR = Polyurethanes
Page 25 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
28. CropScience in Brazil – Gained Share in
One of the World’s Largest Ag Markets
Brazil is the 2nd largest market
for CropScience
Bayer is one of the leading suppliers
and growing strongly
Bayer gained market share in each of
the past 3 years
Risk management systems in place to
limit the potential impact of reduced
credit availability; established barter
business
CropScience sales (in €m)
CAGR
847 +19%
676 724
421 493
2006 2007 2008 2009 2010
Page 26 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
29. More Innovation
Less Administration
Page 27 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
30. €800m Restructuring Program Underway
Contribution by Subgroup Savings Initiative
Savings and efficiency initiative at
Holding & Admin. HealthCare HealthCare, CropScience and
corporate level
~12% Annual cost savings of €800m
starting 2013, reinvestment of ~50%
~34% ~54% One-time-charges of around €1bn by
end of 2012
Plans include reductions of 4,500 people
2,500 new hires in growth and
CropScience innovation, particularly in emerging
markets
Page 28 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
31. Reporting Events and AGM
Date Event Publication
China Conference 2011,
November 16-18, 2011
Shanghai
Tuesday,
Investor Conference Call 2011 Annual Report
February 28, 2012
Thursday, 1st Quarter 2012 Results
Investor Conference Call
April 26, 2012 Stockholders’ Newsletter
Friday,
Annual General Meeting
April 27, 2012
Tuesday, 2nd Quarter 2012 Results
Investor Conference Call
July 31, 2012 Stockholders’ Newsletter
Tuesday, 3rd Quarter 2012 Results
Investor Conference Call
October 30, 2012 Stockholders’ Newsletter
Page 29 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011
32. Investor Relations Contacts
Dr. Alexander Rosar
Head of Investor Relations
Phone: +49-214-30-81013
E-mail: alexander.rosar@bayer.com
Dr. Jürgen Beunink Ute Menke
Phone: +49-214-30-65742 Phone: +49-214-30-33021
E-mail: juergen.beunink@bayer.com E-mail: ute.menke@bayer.com
Peter Dahlhoff Judith Nestmann
Phone: +49-214-30-33022 Phone: +49-214-30-66836
E-mail: peter.dahlhoff@bayer.com E-mail: judith.nestmann@bayer.com
Fabian Klingen Dr. Olaf Weber
Phone: +49-214-30-35426 Phone: +49-214-30-33567
E-mail: fabian.klingen@bayer.com E-mail: olaf.weber@bayer.com
Page 30 • Investor Presentation • Roadshow Frankfurt • Marijn Dekkers, CEO • November 4, 2011